S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:PRTG

Portage Biotech (PRTG) Stock Price, News & Analysis

$0.56
+0.02 (+3.68%)
(As of 03/28/2024 ET)
Today's Range
$0.55
$0.64
50-Day Range
$0.42
$1.07
52-Week Range
$0.34
$4.40
Volume
17,067 shs
Average Volume
60,163 shs
Market Capitalization
$10.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

Portage Biotech MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
1,409.0% Upside
$8.50 Price Target
Short Interest
Healthy
0.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Portage Biotech in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.03) to ($0.65) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.31 out of 5 stars

Medical Sector

315th out of 938 stocks

Biotechnology Industry

12th out of 47 stocks

PRTG stock logo

About Portage Biotech Stock (NASDAQ:PRTG)

Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.

PRTG Stock Price History

PRTG Stock News Headlines

PRTG: Extending the Runway
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Portage Biotech Inc PRTG
H.C. Wainwright downgrades Portage Biotech on financing overhang
Portage Biotech just downgraded at H.C. Wainwright, here's why
PRTG: Bridging I-O: Working in Harmony with Checkpoints
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Portage Biotech Reports Business and Strategic Update
Portage Biotech GAAP EPS of -$0.29
Analyst Expectations for Portage Biotech's Future
Portage Biotech in Keytruda Collaboration With Merck
Portage Biotech Inc (PRTG) Receives a Buy from H.C. Wainwright
See More Headlines
Receive PRTG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Portage Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/29/2024
Fiscal Year End
3/31/2024
Next Earnings (Estimated)
7/29/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Crude petroleum & natural gas
Sub-Industry
N/A
Current Symbol
NASDAQ:PRTG
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.50
High Stock Price Target
$11.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+1,409.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-104,610,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.45 per share

Miscellaneous

Free Float
10,312,000
Market Cap
$10.03 million
Optionable
Optionable
Beta
0.96
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Ian B. Walters M.B.A. (Age 55)
    M.D., CEO & Chairman of Board
    Comp: $967.65k
  • Mr. Allan J. Lee Shaw CPA (Age 60)
    Chief Financial Officer
    Comp: $524.08k
  • Mr. Steven Innaimo
    Vice President of Project Management & Operations
  • Dr. Robert A. Kramer Ph.D.
    Chief Scientific Officer
  • Mr. Brian Wiley (Age 56)
    Chief Business Officer
    Comp: $220.69k
  • Mr. Justin Fairchild
    Vice President of Development
  • Mr. Joseph Ciavarella
    Chief Accounting Officer

PRTG Stock Analysis - Frequently Asked Questions

Should I buy or sell Portage Biotech stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Portage Biotech in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PRTG shares.
View PRTG analyst ratings
or view top-rated stocks.

What is Portage Biotech's stock price target for 2024?

2 Wall Street research analysts have issued 1 year target prices for Portage Biotech's stock. Their PRTG share price targets range from $6.00 to $11.00. On average, they anticipate the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 1,409.0% from the stock's current price.
View analysts price targets for PRTG
or view top-rated stocks among Wall Street analysts.

How have PRTG shares performed in 2024?

Portage Biotech's stock was trading at $1.82 at the beginning of the year. Since then, PRTG shares have decreased by 69.0% and is now trading at $0.5633.
View the best growth stocks for 2024 here
.

Are investors shorting Portage Biotech?

Portage Biotech saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 15,400 shares, a decrease of 84.6% from the February 29th total of 100,200 shares. Based on an average daily volume of 62,600 shares, the short-interest ratio is presently 0.2 days. Approximately 0.2% of the company's stock are sold short.
View Portage Biotech's Short Interest
.

When is Portage Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, July 29th 2024.
View our PRTG earnings forecast
.

How were Portage Biotech's earnings last quarter?

Portage Biotech Inc. (NASDAQ:PRTG) posted its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.09.

Who are Portage Biotech's major shareholders?

Portage Biotech's stock is owned by a number of institutional and retail investors. Top institutional investors include Armistice Capital LLC (10.54%), PEAK6 Investments LLC (0.29%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Portage Biotech?

Shares of PRTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRTG) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners